BLTE

Belite Bio, Inc

Healthcare
Biotechnology
$5.75B market cap

Forecast run · Oct 23, 2026Upside rank 706 of 3,194

Model Signal

ForecastQ Daily Probabilities

44.4%

39.8%

17.1%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$142.78

Price target$245.83

Implied move+72.2%

Analysts6

ForecastQ Portfolios

BLTE is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.